Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial - 14/02/14
This material is based upon work supported by the Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development) and by the National Institutes of Health (NIH K24-AR 02207) to VPW. The Copyright for the CLASI is owned by the University of Pennsylvania. |
|
Funding sources: This funding was supported in part by the National Institutes of Health. |
|
Disclosures: Dr Werth serves as a consultant to Xoma, RPS, Janssen/Centocor, Biogen-Idec, Sanofi-Aventis, UVC, Novartis, Idera, Pfizer, Lupus Foundation of America, Medimmune, Rigel, Merck, Genentech, GSK Stiefel and Celgene. Dr Werth holds stock ownership/options in UV Therapeutics, grants from the NIH, Amgen, Celgene, Rigel, Novartis, and the VA. The copyright for the CLASI is owned by the University of Pennsylvania. No other conflicts of interest were declared. |
|
Trial Registration: Evaluation of lenalidomide (Revlimid) to Treat Subjects with Cutaneous Lupus Erythematosus (CLE). Identified: #NCT00633945. NCT00633945 |
Vol 70 - N° 3
P. 583-584 - mars 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?